Zoetis Inc. (ETR:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.51B -53.8% |
| Revenue (ttm) | 8.34B +1.6% |
| Net Income | 2.31B +1.8% |
| EPS | 5.36 +6.2% |
| Shares Out | n/a |
| PE Ratio | 11.92 |
| Forward PE | 12.24 |
| Dividend | 1.80 (2.71%) |
| Ex-Dividend Date | Jul 20, 2026 |
| Volume | 2,932 |
| Open | 64.22 |
| Previous Close | 65.38 |
| Day's Range | 64.22 - 67.26 |
| 52-Week Range | 61.50 - 135.46 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA...
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
Zoetis Earnings Call Transcript: Q2 2026
Q2 2026 saw flat revenue and a 2% decline in adjusted net income, with U.S. companion animal under pressure from declining clinic visits and heightened competition, while international and livestock segments showed growth. Full-year guidance was revised downward, reflecting persistent headwinds and aggressive competitive activity.
Zoetis Slides: Q2 2026
Zoetis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Zoetis Earnings release: Q2 2026
Zoetis released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zoetis Quarterly report: Q2 2026
Zoetis has published its Q2 2026 quarterly earnings report on August 6, 2026.
Zoetis cuts annual forecasts as pet healthcare demand slows
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competiti...
Zoetis Announces Second Quarter 2026 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The co...
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effe...
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. P...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
Wall Street's Reassessment of Zoetis Accelerated as Analyst Downgrades Followed Each Corrective Disclosure, Reflecting Growing Skepticism That Management's Companion Animal Growth Narrative Was Built ...
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) m...
Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with...
Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a...
Zoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin ...
Zoetis Slides: Corporate presentation
Zoetis has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.
Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2025 Sustainability Report, highlighting progress achieved in 2025 through its Driven to Care strategy. This report marks...
Zoetis Transcript: 46th Annual William Blair Growth Stock Conference
The business continues to prioritize innovation and global expansion, with a robust pipeline targeting key unmet needs in animal health. Despite macro headwinds and increased competition, long-term secular trends and a diversified portfolio support growth. Shareholder returns remain a focus, with significant free cash flow enabling ongoing dividends and buybacks.
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZOETIS, INC. (ZTS)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS).
ZOETIS INC. (ZTS) INVESTOR ALERT Investors With Large Losses in Zoetis Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquire...
Zoetis Transcript: Stifel Jaws & Paws Conference 2026
Guidance for 2026 anticipates 2%-5% organic growth, driven by improvements in OA pain, livestock, and diagnostics, while competitive and macro headwinds persist. No major price resets are planned; focus remains on innovation, targeted promotions, and loyalty programs. New product launches and pipeline investments are expected to support long-term growth.
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor confe...
Zoetis Declares Third Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will b...